MBK-001 is under clinical development by Mikrobiomik Healthcare Company and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase II drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MBK-001 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MBK-001 is under development for the treatment of recurrent Clostridioides difficile infections, non-alcoholic steatohepatitis (NASH), carbapenemase-producing Klebsiella pneumoniae (KPC) infection, metastatic colorectal, metastatic pancreatic and gastric cancer. It is administered through oral route as capsule. It comprises of fecal microbiota and is developed based on Total Fecal Microbiota (TFM) technology.
Mikrobiomik Healthcare Company overview
Mikrobiomik is a biopharmaceutical company, born to research, develop, and market medicines based on human microbiota, providing innovative solutions in chronic diseases. It is headquartered in Euskadi, Spain.
For a complete picture of MBK-001’s drug-specific PTSR and LoA scores, buy the report here.